2016-2017 年美国医院分离株检测普拉佐米星活性：不同折点标准对氨基糖苷类药物敏感性率的影响。
Activity of Plazomicin Tested against Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides.
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02418-19.
Abstract
Plazomicin was active against 97.0% of 8,783 isolates collected in the United States (2016 and 2017), and only 6 isolates carried 16S rRNA methyltransferases conferring resistance to virtually all aminoglycosides. Plazomicin (89.2% to 95.9% susceptible) displayed greater activity than amikacin (72.5% to 78.6%), gentamicin (30.4% to 45.9%), and tobramycin (7.8% to 22.4%) against carbapenem-resistant and extensively drug-resistant isolates. The discrepancies among the susceptibility rates for these agents was greater when applying breakpoints generated using the same stringent contemporary methods applied to determine plazomicin breakpoints.
摘要
硫酸普拉唑米对 2016 年和 2017 年在美国收集的 8783 株分离株中的 97.0%具有活性，只有 6 株分离株携带 16S rRNA 甲基转移酶，对几乎所有氨基糖苷类药物均具有耐药性。硫酸普拉唑米（敏感率为 89.2%至 95.9%）对碳青霉烯类耐药和广泛耐药分离株的活性大于阿米卡星（敏感率为 72.5%至 78.6%）、庆大霉素（敏感率为 30.4%至 45.9%）和妥布霉素（敏感率为 7.8%至 22.4%）。当应用相同的严格当代方法生成的折点来确定硫酸普拉唑米的折点时，这些药物的敏感性率之间的差异更大。
相似文献
1
Activity of Plazomicin Tested against Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides.2016-2017 年美国医院分离株检测普拉佐米星活性：不同折点标准对氨基糖苷类药物敏感性率的影响。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02418-19.
2
Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.比较普拉佐米星与其他氨基糖苷类药物对来自欧洲和邻近国家的分离株的活性，包括对氨基糖苷类修饰酶和其他耐药机制进行分子特征分析的肠杆菌科。
J Antimicrob Chemother. 2018 Dec 1;73(12):3346-3354. doi: 10.1093/jac/dky344.
3
Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.帕拉米韦对美国医院分离的革兰氏阴性和革兰氏阳性菌的活性及氨基糖苷类药物对碳青霉烯类耐药肠杆菌科和产碳青霉烯酶基因的分离株的比较活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00313-18. Print 2018 Aug.
4
In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.在体外，与其他临床相关的氨基糖苷类药物相比，普拉佐米星对碳青霉烯类耐药肠杆菌科的活性。
Diagn Microbiol Infect Dis. 2020 Oct;98(2):115117. doi: 10.1016/j.diagmicrobio.2020.115117. Epub 2020 Jun 20.
5
In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).泊沙康唑对产β-内酰胺酶碳青霉烯类耐药肠杆菌科（CRE）的体外活性。
J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. doi: 10.1093/jac/dkx261.
6
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.普拉佐米星对携带美国人口普查分区中最常见的编码氨基糖苷类修饰酶基因的肠杆菌科分离株的体外活性。
Diagn Microbiol Infect Dis. 2019 May;94(1):73-77. doi: 10.1016/j.diagmicrobio.2018.10.023. Epub 2018 Dec 5.
7
Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.希腊医院耐碳青霉烯肺炎克雷伯菌分离株的全国流行病学研究，涉及到帕拉米韦和氨基糖苷类耐药性。
BMC Infect Dis. 2019 Feb 15;19(1):167. doi: 10.1186/s12879-019-3801-1.
8
Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases.普拉佐米星与较老一代氨基糖苷类药物对肠杆菌科分离株的体外活性比较；氨基糖苷类修饰酶和16S rRNA甲基转移酶的流行情况。
Diagn Microbiol Infect Dis. 2020 Aug;97(4):115092. doi: 10.1016/j.diagmicrobio.2020.115092. Epub 2020 May 23.
9
Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.黏菌素耐药肠杆菌科（包括 MCR-1 产生菌）对普拉佐米星的活性。
J Antimicrob Chemother. 2017 Oct 1;72(10):2787-2791. doi: 10.1093/jac/dkx239.
10
Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli.硫酸帕拉米韦对比阿米卡星、庆大霉素和妥布霉素对多重耐药需氧革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01711-19.
引用本文的文献
1
Performance evaluation of plazomicin susceptibility testing of Enterobacterales on VITEK 2 and VITEK 2 Compact Systems.在VITEK 2和VITEK 2 Compact系统上对肠杆菌科细菌进行普拉佐米星药敏试验的性能评估。
J Clin Microbiol. 2025 Sep 10;63(9):e0044925. doi: 10.1128/jcm.00449-25. Epub 2025 Aug 1.
2
In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains.妥布霉素和其他氨基糖苷类药物对耐多药肺炎克雷伯菌的体外活性。
J Antibiot (Tokyo). 2024 Aug;77(8):548-551. doi: 10.1038/s41429-024-00734-2. Epub 2024 May 8.
3
Evaluation of the susceptibility of clinical isolates of NDM-producing to new antibiotics included in a treatment regimen for infections.评估产NDM临床分离株对感染治疗方案中所包含新抗生素的敏感性。
Front Microbiol. 2024 Apr 5;15:1331628. doi: 10.3389/fmicb.2024.1331628. eCollection 2024.
4
Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.近期临床和实验室标准协会（Clinical and Laboratory Standards Institute）断点变化对氨基糖苷类抗菌谱以及普拉佐米星对美国医疗中心耐多药和耐碳青霉烯类肠杆菌科细菌活性的影响。
Open Forum Infect Dis. 2023 Feb 3;10(2):ofad058. doi: 10.1093/ofid/ofad058. eCollection 2023 Feb.
5
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.耐碳青霉烯类：毒力因子、分子流行病学及治疗选择的最新进展
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
6
New antibiotics for Gram-negative pneumonia.用于治疗革兰氏阴性肺炎的新型抗生素。
Eur Respir Rev. 2022 Dec 21;31(166). doi: 10.1183/16000617.0119-2022. Print 2022 Dec 31.
7
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会 2022 年关于治疗产超广谱β-内酰胺酶肠杆菌科细菌（ESBL-E）、耐碳青霉烯肠杆菌科细菌（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
8
Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.治疗耐药革兰氏阴性菌引起的膀胱炎、肾盂肾炎和前列腺炎的难点：抗菌治疗选择：叙述性综述。
Drugs. 2022 Mar;82(4):407-438. doi: 10.1007/s40265-022-01676-5. Epub 2022 Mar 14.
9
Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.多中心临床评估 ETEST 硫酸帕拉米韦（PLZ）用于肠杆菌科药敏试验。
J Clin Microbiol. 2022 Jan 19;60(1):e0183121. doi: 10.1128/JCM.01831-21. Epub 2021 Nov 10.
10
Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Infections.产碳青霉烯酶感染治疗选择的现状与未来展望
Microorganisms. 2021 Mar 31;9(4):730. doi: 10.3390/microorganisms9040730.
本文引用的文献
1
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.泊沙康唑：一种新型氨基糖苷类药物，用于治疗耐药革兰氏阴性菌感染。
Drugs. 2019 Feb;79(3):243-269. doi: 10.1007/s40265-019-1054-3.
2
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.普拉佐米星对携带美国人口普查分区中最常见的编码氨基糖苷类修饰酶基因的肠杆菌科分离株的体外活性。
Diagn Microbiol Infect Dis. 2019 May;94(1):73-77. doi: 10.1016/j.diagmicrobio.2018.10.023. Epub 2018 Dec 5.
3
Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.2013 年至 2017 年期间，作为加拿大病房监测研究的一部分，从加拿大医院的患者中分离出的革兰氏阴性和革兰氏阳性细菌病原体对普拉佐米星的活性。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.02068-18. Print 2019 Jan.
4
Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.比较普拉佐米星与其他氨基糖苷类药物对来自欧洲和邻近国家的分离株的活性，包括对氨基糖苷类修饰酶和其他耐药机制进行分子特征分析的肠杆菌科。
J Antimicrob Chemother. 2018 Dec 1;73(12):3346-3354. doi: 10.1093/jac/dky344.
5
Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.帕拉米韦对美国医院分离的革兰氏阴性和革兰氏阳性菌的活性及氨基糖苷类药物对碳青霉烯类耐药肠杆菌科和产碳青霉烯酶基因的分离株的比较活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00313-18. Print 2018 Aug.
6
Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.普拉唑米星对大多数氨基糖苷类修饰酶仍具有抗生素活性。
ACS Infect Dis. 2018 Jun 8;4(6):980-987. doi: 10.1021/acsinfecdis.8b00001. Epub 2018 Apr 19.
7
Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.来自巴西50个医疗中心的产碳青霉烯酶肠杆菌科细菌对普拉唑米星的抗菌活性。
Diagn Microbiol Infect Dis. 2018 Mar;90(3):228-232. doi: 10.1016/j.diagmicrobio.2017.11.004. Epub 2017 Nov 10.
8
Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.黏菌素耐药肠杆菌科（包括 MCR-1 产生菌）对普拉佐米星的活性。
J Antimicrob Chemother. 2017 Oct 1;72(10):2787-2791. doi: 10.1093/jac/dkx239.
9
In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).泊沙康唑对产β-内酰胺酶碳青霉烯类耐药肠杆菌科（CRE）的体外活性。
J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. doi: 10.1093/jac/dkx261.
10
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.体外研究新型氨基糖苷类药物普拉佐米星单独及与黏菌素、美罗培南、磷霉素或替加环素联合对产碳青霉烯酶肠杆菌科菌株的活性。
Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9.
Zotero 插件